1. Home
  2. FMS vs INCY Comparison

FMS vs INCY Comparison

Compare FMS & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FMS
  • INCY
  • Stock Information
  • Founded
  • FMS 1996
  • INCY 1991
  • Country
  • FMS Germany
  • INCY United States
  • Employees
  • FMS N/A
  • INCY N/A
  • Industry
  • FMS Misc Health and Biotechnology Services
  • INCY Biotechnology: Commercial Physical & Biological Resarch
  • Sector
  • FMS Health Care
  • INCY Health Care
  • Exchange
  • FMS Nasdaq
  • INCY Nasdaq
  • Market Cap
  • FMS 15.0B
  • INCY 17.0B
  • IPO Year
  • FMS 1996
  • INCY 1993
  • Fundamental
  • Price
  • FMS $26.76
  • INCY $86.85
  • Analyst Decision
  • FMS Sell
  • INCY Buy
  • Analyst Count
  • FMS 2
  • INCY 20
  • Target Price
  • FMS $30.00
  • INCY $80.67
  • AVG Volume (30 Days)
  • FMS 358.2K
  • INCY 1.8M
  • Earning Date
  • FMS 11-04-2025
  • INCY 10-28-2025
  • Dividend Yield
  • FMS 2.13%
  • INCY N/A
  • EPS Growth
  • FMS 23.39
  • INCY 900.04
  • EPS
  • FMS 2.62
  • INCY 4.37
  • Revenue
  • FMS $22,922,038,756.00
  • INCY $4,584,996,000.00
  • Revenue This Year
  • FMS $2.01
  • INCY $16.41
  • Revenue Next Year
  • FMS $3.11
  • INCY $10.86
  • P/E Ratio
  • FMS $20.14
  • INCY $19.88
  • Revenue Growth
  • FMS 0.53
  • INCY 18.87
  • 52 Week Low
  • FMS $18.94
  • INCY $53.56
  • 52 Week High
  • FMS $30.46
  • INCY $88.66
  • Technical
  • Relative Strength Index (RSI)
  • FMS 64.67
  • INCY 59.41
  • Support Level
  • FMS $25.05
  • INCY $81.09
  • Resistance Level
  • FMS $26.00
  • INCY $88.66
  • Average True Range (ATR)
  • FMS 0.33
  • INCY 1.90
  • MACD
  • FMS 0.16
  • INCY 0.02
  • Stochastic Oscillator
  • FMS 95.99
  • INCY 76.09

About FMS Fresenius Medical Care AG

Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.

About INCY Incyte Corp.

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Share on Social Networks: